However, critics argue that the genetic screenings offered by 23andMe provide limited health information and are not a substitute for medical care. Furthermore, there are concerns about the company's handling of customer data, especially in the event of bankruptcy. If 23andMe goes out of business, customer data could potentially be sold off to other companies.
Key takeaways:
- 23andMe is facing financial difficulties and is planning to double down on selling DNA data to pharmaceutical companies.
- CEO Anne Wojcicki has not directly answered whether customers are aware that opting in for research means their data could be shared with pharmaceutical partners.
- 23andMe is trying to rebrand itself as a healthcare service and is offering subscription services, such as 23andMe+ Total Health and 23andMe+ Premium.
- If 23andMe goes out of business, customer data could potentially be sold off to other companies.